{
    "id": 26658,
    "fullName": "B2M L15fs",
    "impact": "frameshift",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "B2M L15fs results in a change in the amino acid sequence of the B2m protein beginning at aa 15 of 119 (PMID: 28194276, PMID: 28466543), likely resulting in premature truncation of the functional protein. Due to the loss of all known functional domains (UniProt.org), L15fs is predicted to result in a loss of B2m protein function.",
            "references": [
                {
                    "id": 9649,
                    "pubMedId": 28466543,
                    "title": "Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28466543"
                },
                {
                    "id": 9646,
                    "pubMedId": 28194276,
                    "title": "A case report of concurrent embryonal rhabdomyosarcoma and diffuse large B-cell lymphoma in an adult without identifiable cancer predisposition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28194276"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 567,
        "geneSymbol": "B2M",
        "terms": [
            "B2M",
            "IMD43"
        ]
    },
    "variant": "L15fs",
    "createDate": "06/28/2017",
    "updateDate": "12/30/2018",
    "referenceTranscriptCoordinates": {
        "id": 91653,
        "transcript": "NM_004048",
        "gDna": "chr15:g.(44711588_44711589)",
        "cDna": "c.(43_42)",
        "protein": "p.L15fs",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20553,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a colorectal cancer patient with high levels of microsatellite instability (MSI-high), B2M V69Wfs*34, and B2M L15fs*41 demonstrated a partial response when treated with a PD-1 therapy (PMID: 31008436).",
            "molecularProfile": {
                "id": 35226,
                "profileName": "B2M L15fs B2M V69Wfs*34 MSI high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20555,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two colorectal cancer patients with high levels of microsatellite instability (MSI-high) and B2M L15fs demonstrated a partial response and stable disease when treated with a PD-1 therapy (PMID: 31008436).",
            "molecularProfile": {
                "id": 35228,
                "profileName": "B2M L15fs MSI high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20559,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colorectal cancer patient with high levels of microsatellite instability, B2M L13P, and B2M L15fs demonstrated stable disease when treated with a PD-1 inhibitor (PMID: 31008436).",
            "molecularProfile": {
                "id": 35231,
                "profileName": "B2M L13P B2M L15fs MSI high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17915,
                    "pubMedId": 31008436,
                    "title": "Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31008436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27950,
            "profileName": "B2M L15fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35226,
            "profileName": "B2M L15fs B2M V69Wfs*34 MSI high",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35228,
            "profileName": "B2M L15fs MSI high",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35231,
            "profileName": "B2M L13P B2M L15fs MSI high",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 91654,
            "transcript": "XM_005254549",
            "gDna": "chr15:g.(44711588_44711589)",
            "cDna": "c.(43_42)",
            "protein": "p.L15fs",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 91653,
            "transcript": "NM_004048",
            "gDna": "chr15:g.(44711588_44711589)",
            "cDna": "c.(43_42)",
            "protein": "p.L15fs",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}